Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab - Diem, S; Schmid, S; Krapf, M (Lung Cancer, 2017)
(July):